SlidesetHIV26th International Workshop on Clinical Pharmacology of HIV, Hepatitis, and Other Antiviral Drugs 2025Abstract #14 Pharmacokinetics of Long-Acting Cabotegravir and Rilpivirine in Seminal Plasma throughout the Dosing Interval - Noah NeveretteView Slideset
SlidesetHIV26th International Workshop on Clinical Pharmacology of HIV, Hepatitis, and Other Antiviral Drugs 2025Abstract #13 Intracellular Carbovir- and Lamivudine-Triphosphate Concentrations in PBMC and DBS among Children with HIV-1 Receiving ABC/DTG/3TC: Results from IMPAACT 2019 - Stefanie SchwabView Slideset
SlidesetHIVTuberculosis26th International Workshop on Clinical Pharmacology of HIV, Hepatitis, and Other Antiviral Drugs 2025Abstract #12 Pharmacokinetics of Abacavir and Lamivudine in Infants with and without Rifampicin Co-Treatment - Laize BecaView Slideset
SlidesetHIVTuberculosis26th International Workshop on Clinical Pharmacology of HIV, Hepatitis, and Other Antiviral Drugs 2025Abstract #11 A Preliminary Analysis of the Impact of Pharmacogenetic Variation on Bictegravir and Dolutegravir Concentrations in Individuals with HIV and Tuberculosis - Anushka NaidooView Slideset
SlidesetHIVTuberculosis26th International Workshop on Clinical Pharmacology of HIV, Hepatitis, and Other Antiviral Drugs 2025Abstract #10 Drug Interactions Between Probe Drugs Dolutegravir (DTG), Midazolam (MDZ) and Digoxin (DIG) with Escalating Doses of Rifampicin (RIF): DORIS Study - Laura DickinsonView Slideset
SlidesetTuberculosis26th International Workshop on Clinical Pharmacology of HIV, Hepatitis, and Other Antiviral Drugs 2025Abstract #9 Physiologically Based Pharmacokinetic Modeling to Inform Lenacapavir Dose Regimen When Co-Administered with Rifamycins in Participants with Tuberculosis - Sara SalernoView Slideset
JCJessica CusatoBSc, MSc, PhDSlidesetViral Hepatitis and Liver Disease26th International Workshop on Clinical Pharmacology of HIV, Hepatitis, and Other Antiviral Drugs 2025Abstract #8 Pharmacogenetic and Pharmacokinetic Profiling of Bulevirtide in Patients with Chronic Hepatitis D: A Preliminary Study - Jessica CusatoView Slideset
JCJessica CusatoBSc, MSc, PhDSlidesetViral Hepatitis and Liver Disease26th International Workshop on Clinical Pharmacology of HIV, Hepatitis, and Other Antiviral Drugs 2025Pharmacology of HDV - Jessica CusatoView Slideset
KWCKeith W. CrawfordRPh, PhDSlideset26th International Workshop on Clinical Pharmacology of HIV, Hepatitis, and Other Antiviral Drugs 2025NIH Initiatives and Research Promoting Antiviral Pharmacology - Keith W. CrawfordView Slideset
Slideset26th International Workshop on Clinical Pharmacology of HIV, Hepatitis, and Other Antiviral Drugs 2025Abstract #7 An Enzymatic Assay for Rapid and Minimally Instrumented Ganciclovir Triphosphate Monitoring in Infants With Congenital Cytomegalovirus - Willow ChernoskeView Slideset
Slideset26th International Workshop on Clinical Pharmacology of HIV, Hepatitis, and Other Antiviral Drugs 2025Abstract #6 Target Attainment of Valganciclovir Prophylaxis against Cytomegalovirus - Suzanne WenkerView Slideset
SlidesetHIV26th International Workshop on Clinical Pharmacology of HIV, Hepatitis, and Other Antiviral Drugs 2025Abstract #5 Plasma Bictegravir/Emtricitabine/Tenofovir Alafenamide Concentrations in Transgender Women with HIV on Estrogen-Based Gender-Affirming Hormone Therapy in Comparison to Cisgender Women Living with HIV - Shawnalyn SunagawaView Slideset
